Experiment: 2LZN

SOLUTION NMR

NMR Experiment
Experiment	Type	Sample Contents	Solvent	Ionic Strength	pH	Pressure	Temperature (K)	Spectrometer
1	2D 1H-15N HSQC	1.4 mM [U-100% 13C; U-100% 15N] primase CTD	90% H2O/10% D2O		6.6	1 atm	298
2	2D 1H-13C HSQC	1.4 mM [U-100% 13C; U-100% 15N] primase CTD	90% H2O/10% D2O		6.6	1 atm	298
3	2D 1H-13C HSQC aliphatic	1.4 mM [U-100% 13C; U-100% 15N] primase CTD	90% H2O/10% D2O		6.6	1 atm	298
4	2D 1H-13C HSQC aromatic	1.4 mM [U-100% 13C; U-100% 15N] primase CTD	90% H2O/10% D2O		6.6	1 atm	298
5	3D CBCA(CO)NH	1.4 mM [U-100% 13C; U-100% 15N] primase CTD	90% H2O/10% D2O		6.6	1 atm	298
6	3D HNCO	1.4 mM [U-100% 13C; U-100% 15N] primase CTD	90% H2O/10% D2O		6.6	1 atm	298
7	3D HNCA	1.4 mM [U-100% 13C; U-100% 15N] primase CTD	90% H2O/10% D2O		6.6	1 atm	298
8	3D HNCACB	1.4 mM [U-100% 13C; U-100% 15N] primase CTD	90% H2O/10% D2O		6.6	1 atm	298
9	3D HCCH-COSY	1.4 mM [U-100% 13C; U-100% 15N] primase CTD	90% H2O/10% D2O		6.6	1 atm	298
10	3D HN(CO)CA	1.4 mM [U-100% 13C; U-100% 15N] primase CTD	90% H2O/10% D2O		6.6	1 atm	298
11	3D 1H-15N NOESY	1.4 mM [U-100% 13C; U-100% 15N] primase CTD	90% H2O/10% D2O		6.6	1 atm	298
12	3D 1H-13C NOESY aliphatic	1.4 mM [U-100% 13C; U-100% 15N] primase CTD	90% H2O/10% D2O		6.6	1 atm	298
13	3D 1H-13C NOESY aromatic	1.4 mM [U-100% 13C; U-100% 15N] primase CTD	90% H2O/10% D2O		6.6	1 atm	298
14	3D HNHA	1.4 mM [U-100% 13C; U-100% 15N] primase CTD	90% H2O/10% D2O		6.6	1 atm	298

NMR Spectrometer Information
Spectrometer	Manufacturer	Model	Field Strength
1	Bruker	DRX	600

NMR Refinement
Method	Details	Software
DGSA-distance geometry simulated annealing		NMRPipe

NMR Ensemble Information
Conformer Selection Criteria	structures with the lowest energy
Conformers Calculated Total Number	2000
Conformers Submitted Total Number	20
Representative Model	1 (lowest energy)

Computation: NMR Software
#	Classification	Version	Software Name	Author
1	processing	NMRPipe		Delaglio, Grzesiek, Vuister, Zhu, Pfeifer and Bax
2	refinement	XPLOR-NIH		Delaglio, Grzesiek, Vuister, Zhu, Pfeifer and Bax

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM133198.